Clinical Trial Detail

NCT ID NCT01967095
Title Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Age Groups: senior adult

No variant requirements are available.